<DOC>
	<DOCNO>NCT01803438</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness Pulmonary Vein Isolation ( PVI ) perform Arctic Front™ Advance Cardiac CryoAblation Catheter System first-line therapy comparison antiarrhythmic drug ( AAD ) patient paroxysmal atrial fibrillation ( AF ) .</brief_summary>
	<brief_title>Catheter Cryoablation Versus Antiarrhythmic Drug First-Line Therapy Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<criteria>Subject diagnose symptomatic paroxysmal atrial fibrillation define least two symptomatic episode last six month prior inclusion . At least one episode AF must document prior year kind ECG recording . Subject structural normal heart LVEF ≥ 50 % , thickness interventricular septum ≤12 mm leave atrium diameter ( short axis ) &lt; 46 mm obtain transthoracic echocardiography . Subject normal ECG parameter ( QRS width 12 channel surface ECG ≤120 m , QTc interval &lt; 440 m , PQ interval ≤ 210 m ; parameter measure sinus rhythm ) . Subject least 18 old 75years old . Subject able willing give inform consent . Subject develop persistent AF least history ( electrical pharmacological cardioversion 48h episode duration &gt; 7 day ) . Subject document typical atrial flutter . Subject history successful unsuccessful treatment AF class I III antiarrhythmic sotalol intention prevent AF recurrence . Patients pretreated AAD maximum 48 hour intention convert AF episode allow . Subject previous leave atrial ablation . Subject previous cardiac surgery , e.g . prosthetic valve . Subject permanent pacemaker defibrillator implant . Subject 2° type II , 3° degree AVblock left/right bundle branch block pattern . Subject unstable angina pectoris . Subject history previous myocardial infarction percutaneous intervention last three month . Subject symptomatic carotid stenosis . Subject chronic obstructive pulmonary disease detect pulmonary hypertension evidence significant lung disease . Subject contraindication oral anticoagulation . Subject history previous transient ischemic attack stroke . Subject know intracardiac thrombus formation . Subject significant congenital heart defect correct ( except patent foramen ovale allow ) . Subject evidence congestive heart failure ( NYHA class II , III IV ) sinus rhythm . Subject hypertrophic cardiomyopathy . Subject abnormal long short QT interval , sign Brugada syndrome , know inherit ion channel disease family , arrhythmogenic right ventricular dysplasia . Subject sarcoidosis . Subject pulmonary vein stent . Subject myxoma . Exclusion criterion base laboratory abnormality Subject thrombocytosis ( platelet count &gt; 600,000 / μl ) thrombocytopenia ( platelet count &lt; 100,000 / μl ) . Subject untreated uncontrolled hyperthyroidism hypothyroidism . Subject renal dysfunction glomerular filtration rate &lt; 60 ml / min . Subject know cryoglobulinaemia . General exclusion criterion Subject reversible cause AF like hyperthyroidism alcoholism . Subject pregnant woman woman childbearing potential adequate birth control : woman highly effective method contraception [ oral contraception intrauterine device ] ( must negative pregnancy test within 1 week start therapy ) sterile woman enrol . Subject breastfeed woman . Subject active systemic infection . Subject employ Medtronic department investigator close relative investigator . Subject unwilling unable comply fully study procedure followup due disease condition , raise doubt compliance influence study outcome especially kind cancer , severe bleed history suspect procoagulant state . Legal incapacity evidence subject understand purpose risk study inability comply fully study procedure follow . Subject life expectancy ≤ 1 year . Subject currently enrol plan participate potentially confound drug device trial course study . Coenrollment concurrent trial allow documented preapproval obtain Medtronic study manager .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>paroxysmal Atrial Fibrillation</keyword>
	<keyword>Cryoablation</keyword>
	<keyword>Pulmonary Vein Isolation</keyword>
</DOC>